You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The researchers are developing an automated machine-learning approach to analyze the expression of protein markers associated with cervical cancer.
The additional €5 million from the European Investment Bank will co-fund R&D across the platforms and product portfolios of Curetis and Ares Genetics.
A research team said the study provides some evidence that there is potential for saliva testing in broad surveillance of past exposure to SARS-CoV-2.
The developer said that use of gold nanoparticles enables use at the point of care and inexpensive signal amplification that eliminates traditional equipment.
The startup is developing a qPCR-based profiling method that could provide results within hours to clinicians treating their cancer patients with immune checkpoint inhibitors.
The group believes its assay, which detects HPV-16 DNA, could be deployed as a screening test in the way that HPV is currently screened to prevent cervical cancer.
The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.
The firm withdrew its 2020 revenue guidance and missed Wall Street estimates for both revenues and earnings.
The firms have already completed proof-of-concept studies for their semiconductor biosensor chips and Roswell plans to have the initial chips by 2021.
Lexogen did not disclose the funding amount, but said it was one of €16 million ($17.4 million) in awards from the Austria Research Promotion Agency.